iREACH Inventory of Resources on Evaluation Methods
Explore evaluation-related checklists, tools, publications, and presentations organized by general evaluation topics assembled by AIM in collaboration with Mathematica.
February Corporate Alliance Webinar (AIM)
This Corporate Alliance meeting on October 28 will allow members to hear the latest on the immunization program landscape and ongoing COVID-19 AIM activities.
Immunization Coalition Toolkit
Explore AIM’s Coalition Toolkit, a comprehensive resource aimed at enhancing the landscape of immunization programs and coalitions.
Infographic: How to Support a Fully-Considered Decision About COVID-19 Vaccination
Learn how you can support decision-making in individuals and consider if, and when a COVID-19 vaccination might be right with this infographic.
iREACH: 2021-2022 Flu Season Talking Points
This talking points document was developed by iREACH Subject Matter Experts to provide information and resources for the 2021-2022 flu season.
FDA Authorized vs FDA Approved
This talking points document was developed by iREACH Subject Matter Experts Dr. Yabo Beysolow and Lisa Jacques-Carroll to provide information on the difference between vaccines that have been authorized by the FDA vs. approved by the FDA.
Tips: Working Together to Address Misinformation
This tip sheet was developed by AIM and NPHIC to help immunization program managers and public information officers collaborate effectively.
COVID-19 Booster Dose Update (AIM)
This talking points document was developed by iREACH Subject Matter Experts Dr. Yabo Beysolow and Lisa Jacques-Carroll to provide updated information on COVID-19 vaccine booster doses.
New York: Resources to Combat Misinformation
The New York government created website resources for the public to combat misinformation about COVID-19 illness and vaccines.
AIM: Talking Points About GBS and J&J Vaccine
This talking points document was developed by iREACH Subject Matter Experts to provide information on the few cases of GBS reported in individuals who received the J & J COVID-19 vaccines.